EPCAM and lip and oral cavity carcinoma: Various EpCAM-targeted immunotherapies that demonstrate promising anticancer activity against oral cancer cells and CSCs, including targeted antibodies, chimeric antigen receptor (CAR) T or NK cells, have been developed.